Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
02 04 2020
Historique:
received: 03 12 2019
accepted: 02 02 2020
entrez: 4 4 2020
pubmed: 4 4 2020
medline: 3 11 2020
Statut: ppublish

Résumé

Anemia is a major and currently poorly understood clinical manifestation of hematopoietic aging. Upon aging, hematopoietic clones harboring acquired leukemia-associated mutations expand and become detectable, now referred to as clonal hematopoiesis (CH). To investigate the relationship between CH and anemia of the elderly, we explored the landscape and dynamics of CH in older individuals with anemia. From the prospective, population-based Lifelines cohort (n = 167 729), we selected all individuals at least 60 years old who have anemia according to World Health Organization criteria (n = 676) and 1:1 matched control participants. Peripheral blood of 1298 individuals was analyzed for acquired mutations at a variant allele frequency (VAF) of 1% or higher in 27 driver genes. To track clonal evolution over time, we included all available follow-up samples (n = 943). CH was more frequently detected in individuals with anemia (46.6%) compared with control individuals (39.1%; P = .007). Although no differences were observed regarding commonly detected DTA mutations (DNMT3A, TET2, ASXL1) in individuals with anemia compared with control individuals, other mutations were enriched in the anemia cohort, including TP53 and SF3B1. Unlike individuals with nutrient deficiency (P = .84), individuals with anemia of chronic inflammation and unexplained anemia revealed a higher prevalence of CH (P = .035 and P = .017, respectively) compared with their matched control individuals. Follow-up analyses revealed that clones may expand and decline, generally showing only a subtle increase in VAF (mean, 0.56%) over the course of 44 months, irrespective of the presence of anemia. Specific mutations were associated with different growth rates and propensities to acquire an additional hit. In contrast to smaller clones (<5% VAF), which did not affect overall survival, larger clones were associated with increased risk for death.

Identifiants

pubmed: 32243522
pii: S0006-4971(20)62138-3
doi: 10.1182/blood.2019004362
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1161-1170

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 by The American Society of Hematology.

Auteurs

Isabelle A van Zeventer (IA)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Aniek O de Graaf (AO)

Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.

Hanneke J C M Wouters (HJCM)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Bert A van der Reijden (BA)

Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.

Melanie M van der Klauw (MM)

Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Theo de Witte (T)

Department of Tumor Immunology and.

Marianne A Jonker (MA)

Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.

Luca Malcovati (L)

Department of Hematology Oncology, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia, Italy; and.
Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Joop H Jansen (JH)

Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.

Gerwin Huls (G)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH